MARKET

MCRB

MCRB

Seres Therapeutics Inc
NASDAQ
12.16
+0.56
+4.78%
Opening 15:04 07/09 EDT
OPEN
11.48
PREV CLOSE
11.60
HIGH
12.80
LOW
11.46
VOLUME
147.68K
TURNOVER
--
52 WEEK HIGH
30.60
52 WEEK LOW
6.53
MARKET CAP
106.14M
P/E (TTM)
1.319
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MCRB last week (0630-0704)?
Weekly Report · 2d ago
Weekly Report: what happened at MCRB last week (0623-0627)?
Weekly Report · 06/30 09:05
Weekly Report: what happened at MCRB last week (0616-0620)?
Weekly Report · 06/23 09:05
Weekly Report: what happened at MCRB last week (0609-0613)?
Weekly Report · 06/16 09:05
Weekly Report: what happened at MCRB last week (0602-0606)?
Weekly Report · 06/09 09:05
Weekly Report: what happened at MCRB last week (0526-0530)?
Weekly Report · 06/02 09:06
Seres Therapeutics presents expanded SER-155 biomarker data at ASCO meeting
TipRanks · 05/27 11:20
Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting
NASDAQ · 05/27 11:13
More
About MCRB
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

Webull offers Seres Therapeutics Inc stock information, including NASDAQ: MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.